News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genomics Collaborative Selected By Sention Inc. For DNA Banking Deal


10/19/2005 5:10:01 PM

Leader in human biological samples provision to supply scientific and clinical expertise to pioneer in neurological pharma

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 16, 2004-- In the newest of a series of DNA-related business, Genomics Collaborative, Inc. (GCI), the leader in providing clinical samples and the application of human genetics to target validation for drug discovery, today announced that it had signed a DNA and serum banking agreement with Sention Inc., a pharmaceutical development company focused on the discovery and development of drugs to treat memory impairment and other central nervous system disorders.

Under the terms of the agreement, GCI will provide expertise in sample collection, processing and management for Sention. GCI will oversee a blood-sample/ DNA collection and banking effort in support of research into an unspecified disease state. GCI will collect and store serum, as well as isolate DNA from whole blood samples collected by Sention in GCI-built collection kits, quality control check the DNA, and store the samples in its automated storage and retrieval system. GCI will also manage the DNA bank on behalf of Sention, retrieving, plating and shipping the samples as needed.

According to Dr. Randall Carpenter, CEO of Sention, "Genomics Collaborative has built a unique base of expertise in biospecimen sample banking. Its compelling combination of scientific, technological and process advantages made it the clear choice to support our DNA-based research program."

Dr. Kevin Krenitsky, Senior Vice President, Business Development of Genomics Collaborative, said, "GCI is very pleased to support Sention's pioneering neurological research, and we applaud their forward-looking approach in applying human genetics to their discovery efforts. Sention fully realizes the importance of injecting the human element into the preclinical phase of R&D, and its irreplaceable value to improving the validation process."

About Genomics Collaborative

Genomics Collaborative, Inc. (GCI) is pioneering the application of human genetics to target validation for drug discovery and diagnostics. GCI's drug validation programs combine access to its Global Repository® of human DNA, tissue and serum with insights from its highly specialized team of human geneticists, statisticians and bioinformaticists.

Open access to the specimens within GCI's Global Repository® allows clients to gain insight into a potential target's value in humans at the earliest possible stages of drug discovery and development. The result is rapid prioritization of the most promising targets for clinical development, potentially shaving years from the discovery-to-commercial drug development pipeline.

Leveraging Global Repository®, GCI offers a spectrum of services ranging from fee-for-service access to human tissue, DNA, and serum samples to customized gene expression and candidate gene validation studies. Global Repository® is the world's largest and most comprehensive library of 550,000 human genetic samples and detailed clinical records, collected from 120,000 patients representing important populations worldwide. GCI's samples represent most pharmaceutically relevant disease states, including common and rare cancers, as well as inflammatory, endocrine, and cardiovascular disorders, and more.

GCI has signed more than 100 partnerships and access agreements with over 40 pharmaceuticals and biotechnology companies, including Pfizer, Inc., Novartis AG, Celera Diagnostics, and Johnson & Johnson, Inc.

For more information, contact Kevin Krenitsky, MD at 617-661-2400, or visit www.genomicsinc.com.

About Sention

Sention is a pharmaceutical development company focused on the discovery and development of drugs for the treatment of disorders related to higher brain functions such as learning and memory. Sention's lead compound, C105, is currently in Phase II clinical trials for the improvement of symptomatic memory impairment associated with various medical conditions. A second compound is in Phase I clinical trials and several additional compounds are in preclinical development. Sention plans to submit a NDA for C105 in 2006.

Sention seeks to build on its scientific and clinical expertise to become the leader in developing drugs to enhance memory. Sention has combined three key elements to craft its strategy: (1) a proprietary drug discovery platform, (2) drugs with established human safety profiles, and (3) indications with short-term development timelines and clearly definable endpoints. This strategy allows Sention to rapidly advance its rich pipeline of leads into clinical development. Sention's success is enhanced by the quality of its management and founding team, which brings together experienced clinical developers, Nobel Prize winning scientists and proven biotech entrepreneurs.

For more information, Shari Annes at 650-888-0902, or visit www.sentionpharma.com.

Contact:

Company Contact Genomics Collaborative, Inc. Kevin Krenitsky, MD, 617-661-2400 KKrenitsky@genomicsinc.com or

Press Contact Boston Communications Mario Fante, 617-619-9805 mfante@bcww.com

Source: Genomics Collaborative, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES